43 results about "TIMP1" patented technology

The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestinal operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor.

The present invention relates to a method for detecting the presence of colorectal cancer in an individual, wherein colorectal cancer is detected by detecting the presence of Reg1α or TIMP1 nucleic acid or amino acid molecules in a clinical sample obtained from the patient, wherein Reg1α or TIMP1 expression is indicative of the presence of colorectal cancer. The invention further relates to a method for detecting the presence of colorectal cancer in an individual, wherein colorectal cancer is detected by detecting the presence of Reg1α or TIMP1 nucleic acid or amino acid molecules in a clinical sample, in addition to detecting the presence of one or more additional colorectal cancer associated markers.

The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix Metalloproteinase-2 (MMP2); thereby promoting arteriogenesis.

The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being:SPP1, andat least one gene from among A2M and VIM, andat least one gene from among IL8, CXCL10 and ENG, andoptionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.

Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.

The invention relates to a detection primer group, a polymerase chain reaction (PCR) detection chip and a detection method for analyzing atherosclerosis related gene expression conditions of human beings and machin. The general atherosclerosis detection primer group for persons and machin comprises amplification primer pairs for respectively amplifying atherosclerosis related genes ACE, APOA1, APOC1, APOF, CCL2, CD40LG, DBP, EDN1, FAS, FASLG, FGG, GLG1, GRN, ICAM1, IL18, IL1beta, IL1RN, IL6, IL6ST, IL8, ITGalpha2beta, ITGalpha4, ITGalpha6, ITGalphaM, ITGalphaV, ITGbeta1, ITGbeta2, LTA, LTB, MTHFR, NFKbeta1, OLR1, PLAUR, PLTP, PON2, SELL, SELP, SELPG, SERPINE1, TIMP1, TNF and TNFRSF1B, and the sequences of the amplification primer pairs are nucleotide sequences shown as SEQ ID NO:1-84. The invention also provides the PCR detection chip containing the primer group and the detection method. The invention can accurately quantify and detect the expression condition of the atherosclerosis related genes of the persons and the machin, and has significance for promotion of basic research of atherosclerosis, prevention detection and clinical treatment.

The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being:SPP1, andat least one gene from among A2M and VIM, andat least one gene from among IL8, CXCL10 and ENG, andoptionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.

The invention relates to a kit for early screening and diagnosis of prostate cancer. The kit comprises upstream and downstream primers of at least two genes of ITGB5, TMEM176B and TMP1, wherein an ITGB5 primer pair is as shown in SEQ ID NO:1 and SEQ ID NO:2; a TMEM176B primer pair is as shown in SEQ ID NO:3 and SEQ ID NO:4; a TIMP1 primer pair is shown in SEQ ID NO:5 and SEQ ID NO:6. The kit disclosed by the invention has ultra-high sensitivity and specificity on the prostate cancer, not only can be used for early diagnosis of the prostate cancer, but also can be used for identifying indolent prostate cancers and actively monitoring the progression of prostate cancer diseases.

The invention relates to the technical field of medicine and bioengineering technology, in particular to a recombinant plasmid based on polyethylene glycol-polylactic acid hydroxyl glycollic acid-polylysine composite nanomaterial entrapment and a preparation method and application thereof. The recombinant plasmid entrapped with a composite nanomaterial is mPPP-pSNAV2-TGFbeta1-IRES-TIMP1 (PSTIT). The invention further provides a preparation method of PSTIT and application of PSTIT in preparing medicine for targeted treatment of diabetic foot (DF) and diabetic peripheral neuropathy (DPN). The invention further provides a novel target for DPN treatment. It is proved through cell experiments and animal experiments that PSTIT can effectively relieve apoptosis of nerve cells of mice with DPN and delay progression of DPN by up-regulating expression of Bcl-2 protein and down-regulating expression of Caspase-3 and Bax protein.

The invention discloses an antibody composition for detecting pancreatic duct adenocarcinoma immunohistochemical marker protein compositions and application of the antibody composition. The pancreatic duct adenocarcinoma immunohistochemical marker protein compositions comprise TIMP1 and CD82. The antibody composition for detecting the protein compositions comprises monoclonal antibodies of the TIMP1 and monoclonal antibodies of the CD82. The antibody composition and the application have the advantages that the TIMP1 / CD82 compositions are used as novel pancreatic duct adenocarcinoma markers, the antibody composition can be widely used in disease identification and diagnosis and prognosis monitoring of pancreatic duct adenocarcinoma, and gaps on immunohistochemical detection in the two aspects can be filled.

The invention discloses the application of a group of serum differential protein combinations in the preparation of reagents for detecting Alzheimer's disease, wherein the serum differential protein combinations are GSN protein, BDNF protein, TIMP1 protein, VLDLR protein and APLP2 protein Any combination of 3 or more proteins. The present invention determines a serum differential protein combination that can be used to detect Alzheimer's disease, and using the serum protein combination to prepare a reagent for detecting Alzheimer's disease can improve the objectivity, specificity and accuracy of detection.